Recombinant Mouse Somatostatin receptor type 5 (Sstr5)
Description
Definition and Classification
Somatostatin Receptor Type 5 (Sstr5) belongs to a family of five receptor subtypes (Sstr1-5) that mediate the diverse physiological actions of somatostatin, a regulatory peptide hormone. These receptors function as cellular gatekeepers, translating extracellular somatostatin signals into intracellular responses across multiple organ systems. Sstr5 is particularly notable for its expression in pancreatic β-cells and intestinal L-cells, suggesting its specialized role in metabolic regulation . As a member of the G-protein-coupled receptor (GPCR) superfamily, Sstr5 shares the characteristic seven-transmembrane domain structure common to this class of signaling proteins, though with distinct ligand specificity and downstream signaling properties that differentiate it from other somatostatin receptor subtypes .
Expression Pattern and Tissue Distribution
Sstr5 displays a distinctive tissue expression pattern that provides important clues to its physiological functions. The receptor is prominently expressed in pancreatic β-cells, where it modulates insulin secretion in response to somatostatin signaling . Additionally, Sstr5 is found in intestinal L-cells, suggesting its involvement in the regulation of incretin hormone release. The receptor's presence in these metabolically active tissues positions it as a key regulator of glucose homeostasis and energy metabolism. Beyond these primary sites, Sstr5 expression extends to various regions within the central and peripheral nervous systems, where it participates in neuronal excitation regulation and related physiological processes .
Genetic Structure and Transcriptional Regulation
The mouse Sstr5 gene has been extensively characterized at the molecular level, revealing important insights into its transcriptional regulation. Research has identified a critical promoter region located approximately 290 base pairs upstream of the transcription start site, with particularly important functional elements concentrated between positions -83 and -19 relative to the transcription initiation point . Through detailed mutational analysis, researchers have further narrowed down the essential regulatory elements, discovering that the region spanning -67 to -47 appears crucial for basal transcriptional activity of the Sstr5 gene in pituitary cells . This region likely serves as a binding site for transcription factors that drive Sstr5 expression in a tissue-specific manner.
Additional regulatory complexity was revealed through deoxyribonuclease I protection assays, which identified protected regions between -61 and -41 as well as -25 and -3 . These protected segments correspond closely with the functionally important regions identified through transfection studies, suggesting they represent binding sites for nuclear factors that control Sstr5 gene expression. Interestingly, mutation analysis revealed differential effects across cell types, with mutations between -26 and -17 reducing promoter activity in GH3 cells but not in TtT-97 thyrotropes, highlighting the cell-type specificity of Sstr5 transcriptional regulation .
Protein Structure and Sequence Analysis
The recombinant mouse Sstr5 protein consists of 362 amino acids, with a molecular structure that conforms to the canonical GPCR architecture. The complete amino acid sequence has been determined, providing essential information for structure-function studies and antibody development . The protein sequence reveals characteristic features of G-protein-coupled receptors, including the seven transmembrane helices that anchor the receptor in the cell membrane. The N-terminal extracellular domain contains sites for post-translational modifications that influence receptor function, while the C-terminal intracellular domain contains phosphorylation sites that regulate receptor signaling and trafficking.
The amino acid sequence of mouse Sstr5 begins with: MEPLSLTST PSWNASAASS SSHNWSLVDP VSPMGARAVL VPVLYLLVCT VGLGGNTLVI YVVLRYAKMK TVTNVYILNL AVADVLFMLG LPFLATQNAV SYWPFGSFLC RLVMTLDGIN QFTSIFCLMV MSVDRYLAVV HPLRSARWRR PRVAKLASAA VWVFSLLMSL PLLVFADVQE GWGTCNLSWP EPVGLWGAAF ITYTSVLGFF GPLLVICLCY LLIVVKVKAA GMRVGSSRRR RSERKVTRMV VVVVLVFVGC WLPFFIVNIV NLAFTLPEEP TSAGLYFFVV VLSYANSCAN PLLYGFLSDN FRQSFRKALD LRRGYGVEDA DAIEPRPDKS GRPQTTLPTR SCEANGLMQT SRL . This sequence information is vital for researchers designing targeted studies of receptor function and developing specific molecular tools for Sstr5 research.
Recombinant Production Systems
Recombinant mouse Sstr5 protein has been successfully produced using mammalian expression systems, particularly HEK-293 cells, which provide the appropriate cellular machinery for proper folding and post-translational modifications essential for receptor functionality . The recombinant protein is typically engineered with affinity tags, such as His-tag, to facilitate purification through one-step affinity chromatography. This approach yields high-purity protein preparations (>90% as determined by Bis-Tris Page and Western Blot) suitable for a range of research applications .
The expression of recombinant Sstr5 in mammalian cells offers significant advantages over bacterial expression systems, particularly for transmembrane proteins like Sstr5 that require complex folding and post-translational modifications. The mammalian cell environment ensures proper receptor trafficking and membrane insertion, preserving the native conformation and functional properties of the receptor. The resulting recombinant protein provides a valuable tool for structural studies, binding assays, and the development of therapeutic agents targeting Sstr5.
Role in Hormone Regulation
In the pituitary gland, Sstr5 participates in the regulation of growth hormone secretion, contributing to the complex neuroendocrine control of growth and metabolism. By mediating the inhibitory effects of somatostatin on somatotroph cells, Sstr5 helps modulate the amplitude and frequency of growth hormone pulses, influencing downstream metabolic processes including protein synthesis, lipolysis, and glucose production. This multifaceted involvement in hormone regulation positions Sstr5 as a key modulator of metabolic homeostasis across multiple physiological systems.
Involvement in Glucose Homeostasis and Insulin Sensitivity
Recent research has revealed a previously underappreciated role for Sstr5 in the regulation of glucose homeostasis and insulin sensitivity. Studies using Sstr5 knockout mice have demonstrated that these animals display enhanced insulin sensitivity compared to wild-type controls, suggesting that Sstr5 normally functions to limit insulin action . This observation has led to exploration of Sstr5 as a potential therapeutic target for improving insulin sensitivity in conditions characterized by insulin resistance, such as type 2 diabetes.
Further investigations using selective Sstr5 antagonists have provided more detailed insights into the mechanisms underlying these effects. In a high-fat diet model of obesity and insulin resistance, Sstr5 knockout mice exhibited significantly lower homeostasis model assessment of insulin resistance (HOMA-IR) scores compared to wild-type controls, indicating improved insulin sensitivity . Similarly, pharmacological inhibition of Sstr5 using a selective antagonist (compound-1) dose-dependently reduced glycosylated hemoglobin levels, plasma glucose, plasma insulin, and HOMA-IR in an obese diabetic mouse model .
Mechanistic studies have revealed that Sstr5 inhibition appears to specifically enhance hepatic insulin sensitivity. Hyperinsulinemic-euglycemic clamp analyses demonstrated that Sstr5 antagonism significantly increased glucose infusion rates while decreasing hepatic glucose production, indicating improved liver insulin action . At the molecular level, Sstr5 antagonism ameliorated the suppression of insulin-induced Akt phosphorylation by octreotide in the liver, suggesting that Sstr5 normally functions to limit insulin signaling in hepatocytes . These findings collectively position Sstr5 as an important regulator of hepatic insulin sensitivity and a potential therapeutic target for improving glucose homeostasis in insulin-resistant states.
Experimental Uses and Tools
Recombinant mouse Sstr5 serves as a valuable research tool for investigating receptor function, ligand binding properties, and downstream signaling pathways. The availability of highly purified recombinant protein enables a range of experimental applications, including Western blotting and SDS-PAGE analyses for studying protein expression and interactions . Additionally, recombinant Sstr5 provides a standardized reagent for developing and validating antibodies, allowing for more specific and reliable detection of the receptor in experimental systems.
For cellular and tissue-based studies, various forms of recombinant Sstr5 antibodies have been developed, including mouse monoclonal antibodies that recognize Sstr5 in both human and rat samples . These antibodies support applications such as immunohistochemistry, immunocytochemistry, flow cytometry, and ELISA, enabling researchers to visualize and quantify Sstr5 expression across different experimental contexts . The availability of labeled antibodies, including Alexa488-labeled and biotin-labeled variants, further expands the toolkit for Sstr5 research, facilitating multiplexed imaging and high-sensitivity detection approaches.
Therapeutic Implications and Drug Development
The emerging understanding of Sstr5's role in metabolic regulation has spurred interest in its potential as a therapeutic target, particularly for metabolic disorders characterized by insulin resistance. Selective Sstr5 antagonists represent a novel class of potential therapeutic agents for type 2 diabetes, operating through a mechanism distinct from current antidiabetic drugs . By enhancing hepatic insulin sensitivity, these compounds could address a fundamental aspect of diabetic pathophysiology, offering new options for patients with inadequate responses to existing therapies.
Experimental evidence supporting this therapeutic approach comes from studies demonstrating that two-week oral administration of a selective Sstr5 antagonist dose-dependently improved glycemic control and insulin sensitivity in diabetic mice . These improvements were associated with specific enhancement of hepatic insulin action, suggesting that Sstr5 antagonism might be particularly beneficial for addressing hepatic insulin resistance, a common feature of type 2 diabetes. As research in this area continues to advance, recombinant mouse Sstr5 provides an essential tool for screening and characterizing novel compounds targeting this receptor, accelerating the drug discovery process.
Product Specs
Note: We will preferentially ship the format that we have in stock. However, if you have a specific format requirement, please indicate it in your order notes. We will fulfill your request if possible.
Note: All of our proteins are shipped with standard blue ice packs by default. If you require dry ice shipping, please inform us in advance, as additional fees may apply.
Generally, the shelf life of the liquid form is 6 months at -20°C/-80°C, while the shelf life of the lyophilized form is 12 months at -20°C/-80°C.
Target Background
- Mouse SSTR5 is sorted by a network of PDZ-domain containing proteins PMID: 24523912
- In contrast to wild-type mice, ApoD(-/-) mice display increased SSTR5-like immunoreactivity in paraventricular nuclei and reduced receptor expression in ventromedial hypothalamus and arcuate nucleus. PMID: 22581439
- Somatostatin inhibits GIP and glucagon-like peptide-1 (GLP-1) secretion from primary small intestinal cultures, partially through SSTR5. PMID: 22872212
- SSTR5 acts as a negative regulator for PDX-1 expression. It may mediate the inhibitory effects of somatostatin and its analogs on insulin expression/secretion and cell proliferation by down-regulating PDX-1 PMID: 22669743
- The discovery of novel truncated SSTR5 variants with unique ligand-selective signaling properties could contribute to a deeper understanding of the complex and distinct pathophysiological roles of somatostatin and cortistatin. PMID: 20063038
- The impact of SSTR2 receptor knockout on SSTR5 receptor mRNA localization and binding sites throughout the brain has been investigated. PMID: 11897118
- The mouse gene promoter has been characterized, and functional activity and nuclear factor interactions have been mapped to two specific promoter regions PMID: 12021191
- Expression of SSTR3, SSTR4, and SSTR5 in mouse proximal tubules complements the expression of SSTR1 and SSTR2 in collecting ducts, as observed in other species PMID: 12472768
- These studies suggest that SSTR5 mediates SRIF inhibition of pancreatic insulin secretion and contributes to the regulation of glucose homeostasis and insulin sensitivity PMID: 12511609
- A role for SSTR-5 in regulating insulin secretion has been proposed. PMID: 12657967
- In AtT-20 cells, SST5 regulates the dominant SST2 action, attenuating SST2 effects on intracellular calcium oscillation and internalization PMID: 15857828
- SSTR5 plays a crucial role in the regulation of insulin secretion in the mouse pancreas PMID: 15919085
- These findings suggest that somatostatin receptor 5 (SSTR5) plays a pivotal role in insulin secretion and glucose regulation in mice, and its regulatory effects are age-related PMID: 16026801
- We identified two sets of SSTR5-regulated pancreatic genes in SSTR5 deficient mice that belong to pathways regulating cell proliferation, apoptosis, neogenesis, angiogenesis, and tumorigenesis. PMID: 19137362
Q&A
What are the structural variants of mouse Sstr5 identified to date?
Mouse somatostatin receptor type 5 exists in multiple structural variants. Research has identified the full-length canonical Sstr5 and three truncated variants that display different numbers of transmembrane domains (TMDs): sst5TMD4, sst5TMD2, and sst5TMD1 . These truncated variants arise through splicing of cryptic introns at the sst5 mRNA and possess unique molecular properties compared to the full-length receptor . The full-length mouse Sstr5 contains the standard seven transmembrane domains characteristic of G-protein coupled receptors (GPCRs), while the truncated variants contain four, two, and one transmembrane domain, respectively .
What is the tissue distribution pattern of mouse Sstr5 variants?
The different Sstr5 variants show distinct but overlapping tissue expression patterns across central and peripheral tissues. Quantitative real-time RT-PCR analysis has revealed that full-length Sstr5 and sst5TMD2 are the most abundantly expressed variants in most tissues, particularly in endocrine and metabolic tissues including the hypothalamus, pituitary, and digestive tract .
| Sstr5 Variant | Hypothalamus | Pituitary | Cortex | Cerebellum | Peripheral Tissues |
|---|---|---|---|---|---|
| Full-length Sstr5 | High | High | Not detected | High | High in endocrine tissues |
| sst5TMD4 | Not detected | Low | Moderate | Not detected | Low expression |
| sst5TMD2 | Moderate | Moderate | High | Moderate | Moderate expression |
| sst5TMD1 | Low | Low | Low | Low | Low expression |
Interestingly, while full-length Sstr5 mRNA was not detected in the mouse cortex, all truncated variants were present at different levels (sst5TMD2 >> sst5TMD4 > sst5TMD1), suggesting potentially important physiological roles for these truncated receptors in cortical function .
How do truncated Sstr5 variants differ in signaling compared to full-length receptors?
When examining calcium responses, cells transfected with full-length Sstr5 respond similarly to both somatostatin (SST) and cortistatin (CST) treatments, with 47% and 40% of cells showing responses, respectively . In contrast, cells expressing sst5TMD4 respond almost exclusively to SST (48% of cells) with minimal response to CST (only 2%) . Intriguingly, sst5TMD2 shows an opposite pattern, with only 13% of cells responding to SST but 51% responding to CST with rapid and clear [Ca²⁺]ᵢ increases . The sst5TMD1 variant shows a moderate response to both ligands, though at lower proportions than the full-length receptor (20% to SST and 11% to CST) .
How do somatostatin and cortistatin differentially regulate cAMP signaling through Sstr5 variants?
The truncated Sstr5 variants exhibit unique cAMP signaling properties in response to somatostatin (SST) and cortistatin (CST). Studies measuring forskolin-induced cAMP accumulation have shown that SST, but not CST, significantly inhibits cAMP production in cells transfected with sst5TMD2 and sst5TMD1 . In contrast, SST tends to potentiate forskolin-induced cAMP accumulation in cells expressing full-length Sstr5 and sst5TMD4, although this effect did not reach statistical significance in some studies .
This differential signaling demonstrates that the truncated structures of these variants result in unique functional properties for each receptor. These findings align with previous research showing that truncated human Sstr5 variants (sst5TMD5 and sst5TMD4) also maintain the ability to convey selective ligand-induced responses .
What structural features are important for agonist binding to Sstr5?
Recent cryo-EM structural studies have revealed critical insights into the molecular basis of Sstr5 activation by different agonists . The binding of cyclic peptide agonists such as cortistatin-17 and octreotide to Sstr5 involves distinct binding modes and conformational changes . Key structural elements involved in agonist recognition include:
-
Extracellular loops that form part of the binding pocket and contribute to ligand selectivity
-
A "hydrophobic lock" mechanism that mediates ligand-specific interactions and receptor activation
-
N-terminal domain interactions that contribute to the ligand-induced activation mechanism
The elucidation of these structural features provides important insights for the development of improved Sstr5 agonists with enhanced selectivity and efficacy for therapeutic applications .
What are the most effective methods for studying the expression of Sstr5 variants in tissue samples?
For accurate detection and quantification of Sstr5 variant expression in tissue samples, quantitative real-time RT-PCR (qrtRT-PCR) with variant-specific primers has proven most effective . When designing primers for truncated variants, special consideration must be given to their unique structures:
-
Design primers that span the joining sites of partial coding regions (CDS-1/CDS-2) of the different truncated Sstr5 variants
-
Validate primer specificity using appropriate controls
-
Use reference genes appropriate for the tissues being studied
-
Consider the relative expression levels of variants (full-length Sstr5 and sst5TMD2 are generally more abundant than sst5TMD4 and sst5TMD1)
For protein-level detection, antibodies specifically targeting unique epitopes of each variant are recommended, though commercial availability may be limited. Epitope tagging approaches (such as HA-tagging) in experimental systems have been successfully employed to study subcellular localization and trafficking .
What experimental models are optimal for investigating Sstr5 function in vitro?
Several experimental models have been successfully employed to study Sstr5 function:
-
Heterologous expression systems: CHO-K1 cells transfected with Sstr5 variants have been widely used to study receptor pharmacology, signaling, and trafficking . These systems allow comparison of the functional properties of different variants in a controlled cellular environment.
-
Primary pituitary cell cultures: These provide a more physiologically relevant model for studying Sstr5 function in endocrine cells . Studies have shown that sst5 and sst5TMD2 mRNAs are expressed in primary pituitary cultures, making them suitable for investigating physiological regulation .
-
Hypothalamic cell lines: The mouse hypothalamic cell line N6 has been used to study the expression and regulation of Sstr5 variants in a neuronal context .
When establishing these models, researchers should consider:
-
Transfection efficiency and expression levels
-
Potential interference from endogenous receptors
-
Appropriate functional readouts (calcium signaling, cAMP accumulation, etc.)
-
The impact of cellular context on receptor function and regulation
What methodological approaches can be used to investigate ligand selectivity among Sstr5 variants?
To investigate ligand selectivity among Sstr5 variants, several complementary approaches can be employed:
-
Calcium mobilization assays: Single-cell calcium imaging has been effectively used to characterize the differential responses of Sstr5 variants to somatostatin and cortistatin . This approach allows for measurement of both the proportion of responsive cells and the temporal characteristics of calcium responses.
-
cAMP accumulation assays: Measuring forskolin-induced cAMP accumulation in the presence or absence of ligands provides insights into the coupling of Sstr5 variants to adenylate cyclase signaling .
-
Ligand binding assays: Radioligand binding studies can determine binding affinities of different ligands to each Sstr5 variant.
-
BRET/FRET-based assays: These can assess receptor-G protein coupling or receptor dimerization in response to different ligands.
When conducting these experiments, researchers should consider:
-
Using multiple ligand concentrations to establish dose-response relationships
-
Including both endogenous (somatostatin, cortistatin) and synthetic ligands
-
Comparing immediate (seconds to minutes) versus delayed (hours) responses
-
Assessing multiple signaling pathways to capture the signaling diversity
How is the expression of Sstr5 variants regulated under different metabolic conditions?
The expression of Sstr5 variants is dynamically regulated under different metabolic and hormonal conditions, with tissue-specific patterns of regulation . Studies in mouse models have revealed distinct regulatory patterns in hypothalamic and pituitary tissues:
-
Fasting conditions: Fasting significantly increases the expression of full-length Sstr5 in the hypothalamus while reducing its expression in the pituitary . In contrast, sst5TMD2 expression is not significantly altered by fasting in either tissue .
-
Diet-induced obesity (DIO): Obesity induced by high-fat diet affects the expression of Sstr5 variants in a tissue-specific manner, with different patterns observed between hypothalamic and pituitary tissues .
-
Leptin deficiency (ob/ob mice): Leptin-deficient obese mice show altered expression patterns of Sstr5 variants compared to wild-type controls .
-
Somatostatin knockout models: Mice lacking endogenous somatostatin (SST-KO) show tissue-specific alterations in Sstr5 variant expression, suggesting compensatory regulation .
These findings indicate that Sstr5 variants are differentially regulated by metabolic signals in a tissue-dependent manner, which may contribute to their diverse physiological roles .
How do endogenous ligands regulate the expression of Sstr5 variants?
Endogenous ligands for Sstr5, primarily somatostatin (SST) and cortistatin (CST), exert differential regulatory effects on the expression of Sstr5 variants . In primary pituitary cell cultures and hypothalamic cell lines, these ligands demonstrate distinct regulatory properties:
This differential regulation by SST and CST suggests ligand-specific and tissue-specific mechanisms controlling Sstr5 variant expression, which may contribute to the complex physiological actions of these peptides .
What is the potential relevance of Sstr5 variants in pathophysiological conditions?
The diverse structural and functional properties of Sstr5 variants suggest potential roles in various pathophysiological conditions, particularly those involving endocrine and metabolic functions . Several areas of pathophysiological relevance include:
-
Neuroendocrine tumors: Given the role of somatostatin analogues in treating pituitary adenomas and other neuroendocrine tumors, the expression pattern of Sstr5 variants may influence therapeutic responses . The ligand selectivity of truncated variants could explain differential responses to specific analogues.
-
Metabolic disorders: The differential regulation of Sstr5 variants under various metabolic conditions (fasting, obesity) suggests potential roles in metabolic homeostasis .
-
Neurological disorders: The expression of truncated Sstr5 variants in brain regions where full-length Sstr5 is absent (such as the cortex) suggests potential neurological functions that remain to be fully characterized .
-
Cancer biology: Altered expression of Sstr5 variants has been observed in various tumors, potentially influencing cell growth, hormone secretion, and response to somatostatin analogue therapy .
Understanding the expression patterns and functional properties of these variants in pathological conditions may lead to improved diagnostic and therapeutic approaches for disorders associated with the somatostatin/cortistatin system .
What strategies can be employed to selectively target specific Sstr5 variants?
Developing strategies to selectively target specific Sstr5 variants represents an important frontier in somatostatin receptor research. Based on current knowledge of the structural and functional differences between variants, several approaches could be considered:
-
Ligand-based selectivity: The differential responses of Sstr5 variants to somatostatin (SST) and cortistatin (CST) suggest the possibility of developing ligands with enhanced selectivity . For example, sst5TMD4 responds almost exclusively to SST, while sst5TMD2 shows preferential responsiveness to CST .
-
Structure-based drug design: The elucidation of the molecular basis for agonist recognition and activation through cryo-EM structures provides a foundation for rational design of variant-selective ligands . Understanding the roles of extracellular loops and the "hydrophobic lock" mechanism in mediating ligand-specific interactions can guide the development of selective compounds .
-
Targeting unique epitopes: The truncated variants possess unique C-terminal tails compared to the full-length receptor . Developing antibodies or other biologics that specifically recognize these unique regions could enable variant-selective targeting.
-
Exploiting subcellular localization differences: The distinct subcellular distribution patterns of different variants (membrane vs. intracellular) could be leveraged to achieve selective targeting . Cell-penetrating peptides might be necessary to target predominantly intracellular variants.
How might the truncated Sstr5 variants interact with the full-length receptor or other GPCRs?
The potential interactions between truncated Sstr5 variants and full-length receptors represent an intriguing area for future research. Several hypotheses and research directions can be considered:
-
Heterodimer formation: Truncated Sstr5 variants might form heterodimers with full-length Sstr5 or other somatostatin receptors (sst1-4), potentially modulating their signaling properties or trafficking. This could explain some of the complex pharmacological profiles observed in tissues expressing multiple variants.
-
Dominant-negative effects: Truncated variants might exert dominant-negative effects on full-length receptor function through direct interaction or competition for binding partners, similar to what has been observed with other truncated GPCR variants such as the corticotrophin-releasing factor receptor type 2α (CRFR2α) .
-
Modification of signaling pathways: The co-expression of truncated variants with full-length receptors might modify downstream signaling pathways, potentially explaining some of the complex, tissue-specific effects of somatostatin and cortistatin that cannot be fully accounted for by the canonical receptors alone .
-
Subcellular compartmentalization effects: The predominant intracellular localization of truncated variants might influence the trafficking or retention of full-length receptors through direct interactions or competition for chaperones or trafficking machinery .
Experimental approaches to investigate these potential interactions could include co-immunoprecipitation, BRET/FRET studies, and functional assays in cells co-expressing multiple variants.
What are the most promising approaches for utilizing Sstr5 knowledge in translational research?
The growing understanding of Sstr5 variants offers several promising avenues for translational research:
-
Improved diagnostics for neuroendocrine tumors: Developing assays to detect the expression profile of Sstr5 variants in tumor samples could improve patient stratification and treatment selection . The differential expression of truncated variants might correlate with tumor behavior or responsiveness to somatostatin analogue therapy.
-
Novel therapeutic approaches: The distinct pharmacological profiles of Sstr5 variants suggest opportunities for developing more selective therapeutic agents . Compounds targeting specific variants might achieve improved efficacy or reduced side effects compared to current somatostatin analogues.
-
Biomarker development: The differential regulation of Sstr5 variants under various metabolic and pathological conditions suggests their potential utility as biomarkers for disease states or treatment response .
-
Understanding treatment resistance: The expression pattern of truncated Sstr5 variants might contribute to resistance to somatostatin analogue therapy in some patients with neuroendocrine tumors . Characterizing these patterns could help identify alternative treatment strategies.
-
Metabolic disease applications: Given the regulation of Sstr5 variants by metabolic conditions and their potential roles in energy homeostasis, targeting specific variants might offer new approaches to treating metabolic disorders .
